Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Vascepa Icosapent Ethyl 26 Reduction In Key Secondary Composite Endpoint Of Cardiovascular Death Heart Attacks And Stroke Demonstrated In Reduce It Supports 25 Overall Reduction In Five Point Major Adverse Cardiovascular Event Primary Composite Endpoint is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 ... Read More
icosapent ethyl
has recommended Amarin’s fish oil-derived drug icosapent ethyl for the prevention of cardiovascular events in ... In March 2020, a Nevada district court judge A Nevada district court judge ruled on ... Read More
press release
but the time-proven value of a press release crafted specifically with the current marketplace in mind is still very much on trend and in fashion. You know the saying "Any press is good press"? Read More
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular ... LDL-C <55 vs ≥55 mg/dL. The primary outcome was a composite of CV death, nonfatal myocardial ... Read More
Submit a Press Release
Your submission must include your full name, organization name, e-mail address and a valid phone number where you can be reached. We also invite you to attach a digital photograph for publication ... Read More
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
The primary outcome was a composite of CV death, nonfatal myocardial infarction, nonfatal stroke ... Design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention ... Read More
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse ... of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE ... Read More
Amarin Corporation plc: New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
The primary outcome was a composite of CV death, nonfatal myocardial infarction, nonfatal stroke ... and Design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention ... Read More
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
24) describing the effects of VASCEPA (icosapent ethyl) on reducing Major Adverse Cardiovascular ... A REDUCE-IT Subanalysis High Lp(a) concentrations are associated with increased CV event ... Read More
New REDUCE-IT ® Analyses Show VASCEPA ®/VAZKEPA ® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
24 describing the effects of VASCEPA ®/VAZKEPA ® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular ... vs ‰¥55 mg/dL. The primary outcome was a composite of CV death, nonfatal ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus